Aurinia Pharmaceuticals Inc (TSE:AUP) (NASDAQ:AUPH) is scheduled to be releasing its earnings data after the market closes on Tuesday, November 14th. Analysts expect Aurinia Pharmaceuticals to post earnings of C($0.19) per share for the quarter.

Shares of Aurinia Pharmaceuticals Inc (TSE AUP) opened at C$7.31 on Monday. Aurinia Pharmaceuticals Inc has a 52-week low of C$2.75 and a 52-week high of C$14.17.

TRADEMARK VIOLATION NOTICE: “Aurinia Pharmaceuticals Inc (AUP) Scheduled to Post Earnings on Tuesday” was first published by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/aurinia-pharmaceuticals-inc-aup-scheduled-to-post-earnings-on-tuesday/1699151.html.

Separately, Seaport Global Securities restated a “buy” rating on shares of Aurinia Pharmaceuticals in a research report on Friday, October 6th.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.